Optimizing Clinical Decisions in Hematologic Malignancies in the Community Setting—Integrating Updates in AML Care to Practice
Pre-test

Questions marked with a * are required
100%
Contact Information
A 62-year-old woman with newly diagnosed AML undergoes a comprehensive genomic analysis. The results reveal a TP53 mutation with chromosomal aneuploidy and complex karyotype. Her initial evaluation shows no significant comorbidities, and her performance status is good.
A 62-year-old woman is diagnosed with AML. Genetic testing reveals the presence of mutated NPM1 without FLT3-ITD. Based on the 2022 European LeukemiaNet (ELN) risk stratification, how would you classify this patient's risk?
A 75-year-old woman with newly diagnosed AML is found to have an IDH1 mutation. She has an ECOG performance status of 2 and a history of congestive heart failure. Which of the following treatment options would be most appropriate for this patient? 
A 62-year-old man with relapsed AML is started on gilteritinib for FLT3-mutated disease. Two weeks into treatment, he develops fever, dyspnea, and peripheral edema. What is the most appropriate next step in management?
Powered by QuestionPro